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OBJECTIVE — Aldose reductase inhibitors (ARIs) are potential disease modiﬁers for diabe-
tes complications. We aimed to determine whether ranirestat, an ARI, could slow or reverse the
course of diabetic sensorimotor polyneuropathy (DSP).
RESEARCH DESIGN AND METHODS — A total of 549 patients with DSP were
randomly assigned to treatment with placebo or 10, 20, or 40 mg/day ranirestat for 52 weeks in
this multicenter, double-blind study. Efﬁcacy was evaluated by nerve conduction studies, the
modiﬁed Toronto Clinical Neuropathy Score (mTCNS), and quantitative sensory tests (QSTs).
RESULTS — Atweek52,thesummedsensory(bilateralsuralplusproximalmediansensory)
nerve conduction velocity (NCV) did not show signiﬁcant changes from baseline (2.0 m/s for
placebo compared with 3.2–3.8 m/s for ranirestat). Signiﬁcant improvement in the summed
motor (peroneal, tibial, and median) NCV was observed with 20 and 40 mg/day ranirestat
treatment at week 12 (P  0.05) and at weeks 24 and 36 and in peroneal motor NCV at weeks
36 and 52 (P  0.05) for the 20 mg/day ranirestat group. The mTCNS and QST results did not
differ among the groups during the study. Ranirestat was well tolerated with no pertinent
differences in drug-related adverse events or in effects on clinical laboratory parameters, vital
signs, or electrocardiograms among the four groups.
CONCLUSIONS — Treatment with ranirestat appears to have an effect on motor nerve
function in mild to moderate DSP, but the results of this study failed to show a statistically
signiﬁcant difference in sensory nerve function relative to placebo.
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S
ensorimotor polyneuropathy is one
ofthemajorcomplicationsofdiabe-
tes with a prevalence of 50% in
both type 1 and type 2 diabetes (1,2). Al-
though the biochemical mechanisms un-
derlying the development of diabetic
sensorimotor polyneuropathy (DSP) are
complexandstillcontroversial,thepolyol
pathway is an important factor. Elevated
blood glucose in diabetic patients leads to
increased activity of aldose reductase, an
enzyme that converts glucose to sorbitol,
one of the alcohol sugars. The result is
accumulation of sorbitol within nerves,
which is associated with oxidative stress
and nerve damage (3). Aldose reductase
inhibitors (ARIs) block the polyol path-
way and should be effective in preventing
the progression of DSP. In fact, an earlier
study showed that inhibition of nerve
sorbitol levels was associated with im-
proved motor nerve conduction veloc-
ity (NCV) and an increase in the density
of small-diameter sural nerve myelin-
ated ﬁbers (4).
AlthoughanumberofARIshavebeen
developed, none have achieved clinical
successfordiversereasons,onebeingthat
not all ARIs penetrate human peripheral
nerves (5,6). Ranirestat (previously
knownasAS-3201),anARIdevelopedby
DainipponSumitomoPharma(Osaka,Ja-
pan),hasdemonstrated65and84%inhi-
bition of sorbitol accumulation in sural
nerves from patients treated for 12 weeks
with 5 and 20 mg/day, respectively (P 
0.001) (7). In a 48-week extension study,
the sensory NCV improved by 1 m/s
relative to baseline (P  0.05) (8). Build-
ing on these phase II study results, we
aimed to determine whether ranirestat
would safely slow or reverse the progres-
sion of DSP compared with placebo treat-
ment for 52 weeks.
RESEARCH DESIGN AND
METHODS— We performed a multi-
center,double-blind,randomized,placebo-
controlled study in which patients
were assigned to 10, 20, or 40 mg/day
ranirestat or placebo administered as a
once-daily dose for 52 weeks. The 40 mg/
day dose was selected to determine
whether a higher ranirestat dose, with
presumed greater sorbitol inhibition,
would improve the efﬁcacy observed in
the phase II study with a maximum dose
of 20 mg/day (7,8). The institutional re-
view boards at the participating centers
reviewed and approved the study before
the start of any study procedures. All pa-
tients provided written informed consent
before screening procedures.
A total of 549 patients were enrolled
in the study using the Interactive Voice
Response System. Entry criteria were age
18–70 years, type 1 or 2 diabetes for at
least6months,stableglycemiccontrolfor
at least 3 months before entry, A1C
7.0%,andthepresenceofbilateralsural
nerve potential amplitude responses of at
least 1.0 V. DSP was diagnosed by the
modiﬁed San Antonio criteria requiring
the presence of two of the following four
criteria: 1) symptoms of DSP, 2) signs of
DSP,3)abnormalnerveconductionstud-
ies (NCS) with at least two abnormal
nerves, and 4) abnormal vibration per-
ception threshold (VPT). The presence of
either of the latter two criteria was re-
quired(9).Patientswithnondiabeticneu-
ropathyorsevereneuropathy(suralnerve
amplitude 1.0 V) were excluded. The
results of NCS and VPT and the entry cri-
teria for each patient were reviewed and
approved by the Central Core Laboratory
before a patient could be randomly as-
signedtoensureconsistencyofstudypro-
cedures and high-quality data (10).
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Screening included a medical history,
physical and neurological examinations,
NCS, and quantitative sensory tests
(QSTs) including VPT, cold detection
threshold (CDT), and monoﬁlament sen-
sitivity. The modiﬁed Toronto Clinical
Neuropathy Score (mTCNS) was used as
a potentially more sensitive measure for
clinical change than the validated TCNS
(11). At weeks 12, 24, 36, and 42, NCS
and QSTs were repeated and the mTCNS
was again determined.
The primary end point was the
summed change in sensory NCV from
baseline of bilateral sural and proximal
median sensory nerves. Secondary end
points were the changes for individual
sensory NCV, summed and individual
motor NCV, F wave latencies, QST re-
sults, and the mTCNS.
Electrophysiology measurements.
Testing was standardized for tempera-
ture, side of testing, stimulation protocol,
averaging of sensory potentials, and mea-
surement of latencies and amplitudes.
Unilateral NCS were performed on the
nondominant median motor, dominant
peroneal motor, and nondominant me-
dian sensory nerves. Bilateral sural NCS
were performed. Sensory NCS were per-
formed antidromically. Distances, re-
sponse latencies, and amplitudes were
measured using onset latencies and base-
line-to-peak amplitudes. Measurements
from the initial positive peak, if present,
to the negative peak were made for sen-
sory NCS. F waves were obtained for all
motor nerves, and the minimal reproduc-
ible latency was measured. Conduction
velocities were calculated for motor and
sensory nerves.
mTCNS. The mTCNS consists of graded
symptom and sensory test scores associ-
ated with DSP in the judgment of the ex-
aminer (12). Details of the mTCNS have
been presented previously in a validation
study (12). The individual symptoms and
signs evaluated are identical with those
fortheoriginal,validatedTCNS(11).The
scale varies from 0 (no signs or symptoms
of DSP) to 33 (maximal symptoms and
signs of DSP) with a maximum of 18
symptom points and 15 sensory test
points.
QSTs. TheVPTandCDTweremeasured
at the ﬁrst toe by the method of limits
using the TSA-II NeuroSensory Analyzer
(Medoc, Ramat, Yishai, Israel).
Biochemical measurements. Tandem
Laboratories (Salt Lake City, UT) per-
formedtheranirestatplasmaassays.Sam-
ples were prepared by a solid-phase
extraction procedure and were analyzed
by liquid chromatography/tandem mass
spectrometry. Calibration standards were
prepared by spiking blank, homogenized
human plasma with the appropriate spik-
ing solutions provided by Dainippon
Sumitomo Pharma. The API 3000 system
was operated in the selected-reaction
monitoring mode under optimized con-
ditions for detection of ranirestat negative
ionsformedbyTurboIonSprayionization
(13).
Statistical analyses
Demographic and baseline characteristics
were analyzed for homogeneity using a
Kruskal-Wallis 
2 test. An intention-to-
treat analysis was performed. Within-
group comparisons between the baseline
and end of treatment value were assessed
using a Student’s paired t test. ANCOVA
was constructed to test for effects of treat-
ment. Groups were compared using an
ANCOVA model including baseline val-
ues as covariates. Medically meaningful
predeﬁned covariates were not included
in the model if they were found to be ho-
mogeneous at baseline. Because of differ-
ences in the number of patients between
dose groups and between centers, the
changes are expressed as least-squares
means (LSMs) and were statistically ana-
lyzedwithbaselineasacovariate.Pvalues
were adjusted for multiplicity using Dun-
nett’s procedure. Missing observations
were handled by the last observation car-
ried forward method.
RESULTS — Of 1,645 patients screened,
549patientsfulﬁlledtheentrycriteriaand
were randomly assigned: 134 to placebo,
138 to 10 mg/day ranirestat, 132 to 20
mg/day ranirestat, and 145 to 40 mg/day
ranirestat. Two patients assigned to 10
mg/day ranirestat were not included in
safety and efﬁcacy evaluation because
they did not take any study medication.
The patient demographic data are shown
inTable1.Nosigniﬁcantdifferenceswere
observed among the treatment groups for
sex, age, BMI, type of diabetes, duration
of diabetes, duration of DSP, or A1C. For
all patients, the mean baseline BMI was
33.1 kg/m
2, and most patients (83%) had
type 2 diabetes for 14.5 years and DSP for
4.9 years. Their baseline A1C was 8.3%.
NCS and mTCNS data at screening are
Table 1—Patient baseline demographic information
Placebo
Ranirestat
All patients P 10 mg/day 20 mg/day 40 mg/day
n 134 136 132 145 547
Male sex 74 (55.2) 94 (69.1) 83 (62.9) 91 (62.8) 342 (62.5) 0.134
Age (years) 56.1  8.9 56.2  8.5 55.7  9.2 54.5  9.5 55.6  9.0 0.342
BMI (kg/m
2) 32.9  6.9 32.9  6.9 32.9  6.0 33.5  7.5 33.1  6.8 0.821
Type 2 diabetes (%) 111 (82.8) 120 (88.2) 104 (78.8) 119 (82.1) 454 (83.0) 0.222
Duration of diabetes (years) 14.6  9.0 13.4  8.2 16.0  10.7 14.1  9.0 14.5  9.3 0.136
A1C (%) 8.3  1.3 8.1  1.4 8.3  1.4 8.4  1.4 8.3  1.4 0.219
Duration DSP (years) 4.6  3.2 4.9  3.8 5.3  4.2 4.7  4.0 4.9  3.8 0.536
Symptoms 4.7  3.7 5.1  3.6 4.7  3.3 5.2  4.2
Sensory tests 5.6  3.6 6.1  3.2 5.5  3.5 6.4  3.9
Right sural CV (m/s) 42.5  5.2 41.0  5.1 42.0  5.7 41.7  4.8
Peroneal CV (m/s) 40.5  5.2 39.7  3.9 40.1  4.8 39.5  4.7
Data are n (%) for sex and type of diabetes and means  SD for other parameters. P values for sex and type of diabetes were obtained from 
2 tests. P values for the
other parameters were obtained from ANOVA. Symptoms and sensory tests are domains of the mTCNS. Symptoms range from 0 to 18 and sensory tests from 0 to
15. CV, conduction velocity.
Bril and Associates
DIABETES CARE, VOLUME 32, NUMBER 7, JULY 2009 1257alsoshowninTable1.Themeanvaluefor
eachsymptominthemTCNSwas1and
was somewhat higher for each sensory
test, introducing a ﬂoor effect.
Patient commitment was shown by
the 85.7% who completed the entire 12-
month study. The most common cause
for discontinuation was voluntary with-
drawal in 5.5%. Other reasons for not
completing the study were adverse events
in 1.8%, lack of compliance in 2.2%, lost
tofollow-upin2.2%,failedtocontinueto
meet entry criteria in 2.2%, and other in
0.4%. There was no difference in reasons
for withdrawal across the different treat-
mentgroups.Theaveragecomplianceper
visit was greater than 94% in each treat-
ment group.
For the summed sensory NCV of the
bilateral sural and proximal median sen-
sory nerves, the observed mean  SD
changes from baseline to week 52 were
2.0  7.98 m/s in the placebo group,
3.2  7.98 m/s in the 10 mg/day group,
3.88.45m/sinthe20mg/daygroup,and
3.6  9.33 m/s in the 40 mg/day group.
For the purposes of inferential statistical
analysis by the LSM method, these
changes are 1.17, 1.55, 2.55, and 2.50
m/s for placebo and 10, 20, and 40 mg/
day ranirestat, respectively, at week 52.
These differences did not achieve statisti-
cal signiﬁcance between treatment
groups. Figure 1 shows the LSM change
from baseline for the summed sensory
NCV.
Figure 2 shows the LSM change from
baselineinthesummedmotorNCVofthe
tibial, peroneal, and median nerves. A
mean decrease (deterioration) in the
summedmotorNCVoccurredatweek12
in the placebo group compared with
meanincreases(improvement)inallrani-
restat groups. There were signiﬁcant dif-
ferences between 20 mg/day ranirestat
and placebo (P  0.028) and between 40
mg/day ranirestat and placebo (P 
0.002)atweek12,whentheLSMchanges
from baseline were –0.54 m/s in the pla-
cebo group, 0.65 m/s in the 10 mg/day
group, 1.35 m/s in the 20 mg/day group,
and 1.94 m/s in the 40 mg/day group.
These results remained consistent at sub-
sequent visits.
The peroneal motor NCV improved
with ranirestat treatment signiﬁcantly at
weeks 36 (P  0.05 to P  0.01) and 52
(P  0.014, 0.015, and 0.108 for 10, 20
and 40 mg/day ranirestat, respectively)
with ranirestat treatment compared with
aslightdeteriorationoftheLSM0.1m/sat
week 52 in the placebo group (Fig. 3).
The F-wave latencies also increased
(worsened) in the placebo group com-
pared with decreased latencies (improve-
ment) in the 20 and 40 mg/day ranirestat
groups at most visits (data not shown).
The mTCNS total, symptom, and
sensory test scores tended to decrease
(improve) in all treatment groups (in-
cluding placebo), resulting in no statis-
tically signiﬁcant differences. A
decrease in mTCNS (improvement) was
observed in all groups as early as 12
weeks, and the decrease in mTCNS per-
sisted (or decreased more) during the
study in all groups to week 52 without
signiﬁcant differences between groups.
The decrease in the mTCNS at week 52
was –2.75 points in the placebo group
and varied from –2.4 to –2.75 in ranir-
estat groups (data not shown). Both
VPT and CDT improved at every visit in
all groups, but the differences did not
achieve statistical signiﬁcance between
ranirestat and placebo.
Figure 1—Changes from baseline in the summed sensory NCV. Summed sensory NCV includes
bilateral sural and proximal median sensory nerves. Data shown are LSM  SEM change from
baseline for last observation carried forward. Adjusted P values: placebo vs. 10 mg (P  0.962),
20 mg (P  0.246), and 40 mg (P  0.369) at week 52.
Figure 2—Changes from baseline in the summed motor NCV. The summed motor NCV includes
themedian,peroneal,andtibialnerves.DatashownareLSMSEMchangefrombaselineforlast
observation carried forward. Adjusted P values: placebo vs. 10 mg (P  0.247), 20 mg (P 
0.028), and 40 mg (P  0.002) at week 12; placebo vs. 10 mg (P  0.296), 20 mg (P  0.152),
and 40 mg (P  0.036) at week 24; placebo vs. 10 mg (P  0.188), 20 mg (P  0.029), and 40
mg (P  0.013) at week 36; placebo vs. 10 mg (P  0.913), 20 mg (P  0.123), and 40 mg (P 
0.162) at week 52.
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portionaltodose,anindicationoflinear
pharmacokinetics. The mean values
were consistent over time, without evi-
dence of ranirestat accumulation or
autoinduction.
The incidence of adverse events was
comparable in all groups and led to pre-
maturewithdrawalof2.2%patientsinthe
placebo group, 1.5% patients in the 10
mg/day group, 2.3% patients in the 20
mg/day group, and 1.4% patients in the
40 mg/day group. Ranirestat had no rele-
vant effects on clinical laboratory param-
eters including liver and renal function
tests.
CONCLUSIONS — The results of
this study did not show a signiﬁcant dif-
ference between ranirestat and placebo
treatment in the primary efﬁcacy end
point (change in summed sensory NCV)
perhaps because of the unexpected pla-
cebo improvement. In the previous phase
II study, the changes in the summed sen-
sory NCV with placebo treatment at week
12 ranged from –0.21 to 0.20 m/s,
whereasachangefrombaselineof2.1m/s
was observed at 12 weeks in the placebo
groupinthecurrentstudy(7).Theexpla-
nation for the differences in behavior of
theplacebogroupsbetweenthetwostud-
ies is unclear because the patient popula-
tions are similar with the same entry
criteria and only a small difference in BMI
between the two study populations was
noted. A placebo response has been ob-
served in other recent studies of DSP and
may result from lifestyle modiﬁcation by
the patients as they enter a clinical trial
(14,15). Lifestyle behavior (such as regu-
lar assessment of weight and BMI during
the study) needs to be examined in much
more detail in future studies than was
done in the current study to determine
whether this was the full explanation for
the differences in placebo group behav-
ior. A phase II proof-of-concept study
completed in Japan demonstrated a sig-
niﬁcant improvement in the summed
sensory NCV with ranirestat compared
with placebo after 26 weeks of treat-
ment although the placebo group in
this study also improved (T.-H., per-
sonal communication).
The changes in motor and sensory
nerve conduction parameters differed in
this study, and there is no good explana-
tion for this observation. Both summed
and individual motor NCS parameters
showed improvements with ranirestat
treatmentcomparedwithdeteriorationin
patients treated with placebo. The im-
proved peroneal motor NCV with ranir-
estat treatment suggests clinical beneﬁt
because an abnormal peroneal motor
NCV has been associated with the devel-
opment of foot ulcers and mortality
(16,17). One possible reason for the dif-
ferences observed in sensory and motor
NCV results in this study compared with
those in the earlier phase II study is that
sensory NCS are more technically chal-
lenging to perform than motor NCS be-
cause of the magnitude of the signals
(sensory potential amplitudes are mea-
suredinmicrovoltscomparedwithmotor
potential amplitudes measured in milli-
volts). As a result, factors such as limb
edema may have more of an impact on
sensoryrecordingsthanonmotorrecord-
ings.Thesuralnerveisthemostchalleng-
ing (of the nerves tested in this study) to
evaluate because of anatomic variations
and the small size of the sural nerve re-
sponse. As the number of study sites in-
creased and the BMI of the patients
increased from the phase II study, it is
possible that these factors played a role in
the results consistent with the observed
higher standard deviations of the baseline
parametersinthisstudy.Theuseofacen-
tralcorelaboratorycanminimize,butnot
eliminate, technical barriers in DSP stud-
ies; standardization of procedures across
centers is also essential. The balance be-
tweenincludingmanycenterstodecrease
the recruitment time for the study and
including fewer centers with tightly con-
trolled procedures needs to be kept in
mind for future studies on DSP.
The mTCNS did not show a differ-
ence between the placebo and ranirestat
treatment groups. In addition to an unex-
pected placebo effect perhaps due to life-
style modiﬁcation, another possible
explanation for the lack of differences in
the mTCNS response is the ﬂoor effect.
Six symptoms are evaluated in the
mTCNS,andthemeansymptomscoreon
entry was 5. This score means that each
symptom was 1 at entry, a level that
leaves very little room for a signiﬁcant
changewithtreatment;i.e.,thereisaﬂoor
effect.Similarcommentsapplytothesen-
sory tests. Current criteria are set to cap-
ture patients at a stage of DSP that will
respond to treatment. Abnormalities in
NCS and/or QSTs are required for entry,
but symptoms and signs are not essential,
although the majority of patients have
both when they enter these clinical trials.
DSP is at a mild to moderate stage using
these entry criteria as shown by sural
nerve morphology from prior studies, so
the study population desired has been
captured, but it is likely that clinical
changes cannot be expected after only 12
monthsoftreatmentandthatlongertreat-
ment intervals are essential to demon-
strate clinical effects (4,11). Alternatively,
onlypatientswithmarkedsymptomsmay
be recruited, but then it is uncertain
whether severity would be uniform, as
symptoms are a poor guide to the under-
lying pathological changes in DSP. Deter-
mination of a drug effect on harder end
points (such as frequency of foot ulcer-
ation) requires much larger study co-
horts,patientswithmoreadvancedstages
ofDSPwhenfootulcerationismorelikely
Figure 3—Changes from baseline in peroneal motor NCV. *P  0.05; **P  0.01. Data shown
are LSM  SEM change from baseline for last observation carried forward. Adjusted P values:
placeboversusranirestatalldosesatweek36(P0.035);placebovs.10mg(P0.014),20mg
(P  0.015), and 40 mg (P  0.108) at week 52.
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treatment such as 5-year studies.
The results of this study lend support
to the importance of the polyol pathway
in the pathophysiology of DSP and show
that inhibition of the polyol pathway by
the ARI ranirestat improves motor nerve
function parameters. The placebo re-
sponse and appropriate efﬁcacy variables
remain continuing challenges in ARI de-
velopment, and important lessons have
been learned from the current study. Ra-
nirestat continues to hold promise for the
treatment of patients with DSP.
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